MRD testing in myeloma takes center stage

Submitted by blackswan on Thu, 11/12/2015 - 22:43

Last week’s 4th Annual ESLHO (European Scientific foundation of Laboratory Hemato Oncology) Symposium in Zurich, Switzerland was the first ever dedicated exclusively to examining “New Developments in MRD Diagnostics.” The two-day event provided a comprehensive review of the current status of MRD (minimal residual disease) testing and future optio

What Causes Myeloma? New Study Suggests Random Mutations Are Important

Submitted by Dr. Brian GM Durie on Thu, 01/08/2015 - 22:18

A new study published in Science magazine and reported in the New York Times this week shows that random mutations in normal tissues are more important than previously thought. The study, conducted by Johns Hopkins Medicine researchers Cristian Tomasetti and Bert Vogelstein, did not analyze myeloma, but developed principles that apply broadly for all cancers.

Diagnosing Myeloma Early: New IMWG Guidelines

Submitted by Dr. Brian GM Durie on Mon, 10/27/2014 - 00:00

For some time, members of theInternational Myeloma Working Group (IMWG), the IMF's research division, have been trying to identify and describe a group of patients without 

Frontline Therapy and MRD: Exciting New Data from France

Submitted by Dr. Brian GM Durie on Thu, 07/31/2014 - 00:00

A recent study illustrates just how useful minimal residual disease (MRD) testing by flow cytometry is to predict excellent outcomes with new highly active combination therapies.

US Myeloma Flow Workshop in New York

Submitted by Dr. Brian GM Durie on Thu, 07/24/2014 - 00:00

On July 18-19, 2014, the IMF co-hosted the US Myeloma Flow Workshop at the Zuckerman Research Center at the Memorial Sloan Kettering Cancer Center in New York City. There were 24 participating medical centers from across the country plus representatives from the National Cancer Institute (NCI) and US Food and Drug Administration (FDA) in attendance.

Pages